Sutro Biopharma, Inc. (STRO)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Sutro Biopharma, Inc. (STRO) is listed on Nasdaq, where it has traded since September 27, 2018.
- Listed On
- Nasdaq
- Listed Since
- September 27, 2018
- Employees
- 128
- Market Cap
- $154M
About Sutro Biopharma, Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 97 institutions reported holding STRO, with 16.5 million shares worth $545.7 million in aggregate. The largest reported holder was Perceptive Advisors, with 1.3 million shares worth $43.3 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Perceptive Advisors | 1,304,846 | $43M | Added 82.42% |
| Bvf Inc/IL | 1,251,788 | $42M | Unchanged |
| Affinity Asset Advisors | 1,172,487 | $39M | Added 9.63% |
| BlackRock | 1,122,655 | $37M | Added 382.48% |
| Samsara Biocapital | 1,062,872 | $35M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is STRO?
Sutro Biopharma, Inc. (STRO) is listed on Nasdaq, where it has traded since September 27, 2018.
Who are the largest institutional holders of STRO?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of STRO were Perceptive Advisors, Bvf Inc/IL and Affinity Asset Advisors.
How many institutions own STRO?
97 institutions reported a position in STRO for the quarter ended June 30, 2026, worth $545.7 million in total.
Did institutions buy or sell STRO last quarter?
Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for STRO.
Every reported institutional holder, plus insider and congressional trades in STRO, on SentiSense.